Scrip Intelligence interviewed Mattias Ivarsson at BIO Europe 2016 in Cologne. The video can be found here.
- Interview of Inositec CEO by Scrip Intelligence
- Inositec AG Secures CHF1.4 million in Seed Financing to Advance New Class of Inositol Hexaphosphate-Based Drug Candidates
- Inositec nominated for the 2016 deVigier prize
- Inositec CEO named on Forbes 30 under 30 list
- Inositec CEO featured in ETH Globe magazine
Inositec AG Secures CHF1.4 million in Seed Financing to Advance New Class of Inositol Hexaphosphate-Based Drug Candidates
Lead programs address unmet medical needs in vascular calcification and C. difficile infection
Zurich, Switzerland, 27th October 2016 – Inositec, a pioneer in the development of life-saving small molecule drugs based on inositol hexaphosphate (IP6), announced today the closing of a CHF1.4 million (US$1.42 million) seed financing. Investors participating in the round included VI Partners via the Venture Incubator fund and Zürcher Kantonalbank. The proceeds will be used to progress a drug candidate from Inositec’s proprietary Inositune platform through preclinical proof-of-concept.
“Inositol hexaphosphate is a naturally occurring substance that acts as a messenger in cells and is involved in multiple biochemical pathways,” explained Dr. Mattias Ivarsson, CEO of Inositec. “Using this molecule as a starting point, we have created a new class of compounds that have been specifically designed to address various therapy areas. Our programs address significant medical needs in vascular calcification and Clostridium difficile infection. This financing will enable us to advance a lead candidate from one of these programs through preclinical evaluation and ready for progression to clinical studies.”
In conjunction with the financing. Michael Wacker, PhD, was appointed as Chairman of the Board of Directors. Dr. Wacker is a serial entrepreneur, co-founding several companies including GlycoVaxyn and Limmatech. He also coaches start-ups in Switzerland for CTI, the governmental commission of technology and innovation.
“Inositec has made tremendous progress since its founding in December last year. I have been very impressed by the broadly applicable technology as well as the dedicated manner in which the team is building the company,” stated Dr. Wacker. “Inositec’s compounds have significant promise in multiple therapeutic areas where there is a great need for new, effective medicines. I look forward to working alongside the management team to help deliver on this huge potential.”
Inositec is pioneering the development of life-saving small molecule drugs based on inositol phosphate, a natural facilitator of diverse cellular functions. Using its broadly applicable Inositune™ technology to adjust the chemical and physical properties of inositol phosphate analogs, Inositec is developing a novel class of drugs initially focusing on two areas of high-unmet medical need: calcification disorders and Clostridium difficile infection. Inositec was founded in December 2015 based on the award-winning research of Dr Mattias Ivarsson, Prof Jean-Christophe Leroux and Prof Bastien Castagner at ETH Zurich, Switzerland. Further information can be found at www.inositec.com.
About VI Partners
VI Partners is a Swiss venture capital firm and advisor to Venture Incubator (VI). VI was established by McKinsey & Company and the Swiss Federal Institute of Technology in Zürich (ETHZ) in 2001. VI is an evergreen fund with a paid in capital of CHF 101m. The investors are 10 Swiss blue-chip companies from industry and finance. For further information visit www.vipartners.ch.
CEO and Co-Founder Partner
+41 44 271 07 55
+44 (0)20 7318 2955
Inositec has been short-listed together with 10 nominees for the deVigier prize. More info here.
29th March 2016
Mattias Ivarsson appeared in the Science and Healthcare category of the 2016 Forbes 30 under 30 European list.
1st March 2016
Mattias Ivarsson has a vision: he wants to keep a dangerous pathogen in check using an innovative approach. As a Pioneer Fellow, he is now taking his first steps on the path to making that vision a reality. Click here for the article (page 28)
9th December 2015
Three Zurich-based start-ups were awarded this year’s Heuberger Winterthur Start-up Award. The three companies from the Life Sciences field each received CHF 150,000 in prize money. Three other start-ups were awarded CHF 50,000 each. Click here for an article and radio interview in German. Click here for an article in English.
13th November 2015
Mattias Ivarsson is committed to fighting a nasty bacterium at the root of many hospital-acquired infections. This article describes the story behind Inositec’s technology and CEO.
10th November 2014
Swiss national radio interviews Mattias Ivarsson about Inositec’s therapeutic approach to treat Clostridium difficile infection (in French).
6th November 2014
Inositec’s CEO wins the jury and audience prize at the Falling Walls Lab in Zurich and is invited to attend the Falling Walls Lab Final, Conference and Circle in Berlin!
24th September 2014